Impact of gum treatment on blood sugar control in type 2 diabetes patients
Effect of Periodontal Treatment on Metabolic Control in Patients with Type-2 Diabetes Mellitus Treated in the Cardiovascular Healt Program
This study is testing if gum treatment can help people with type 2 diabetes better control their blood sugar levels over a year.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 80 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Chile Academic / other |
| Locations | 1 site (Santiago, Providencia) |
| Trial ID | NCT06895980 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to assess how non-surgical periodontal treatment affects glycated hemoglobin (HbA1c) levels in adults with type 2 diabetes mellitus and periodontitis. Participants will receive periodontal treatment and undergo follow-up assessments of their HbA1c levels and quality of life using the OHIP-14sp survey over a period of one year. The study will track changes at 3, 6, 9, and 12 months to evaluate the effectiveness of the treatment.
Who should consider this trial
Good fit: Ideal candidates are adults diagnosed with type 2 diabetes mellitus and periodontitis, with HbA1c levels of 7% or higher.
Not a fit: Patients who have received periodontal treatment in the past year or are currently pregnant or lactating may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could lead to improved blood sugar control and overall health for patients with type 2 diabetes and periodontal disease.
How similar studies have performed: Previous studies have indicated potential benefits of periodontal treatment on metabolic control in diabetic patients, suggesting this approach may be promising.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 1a. Patients enrolled in the PSCV with a diagnosis of type 2 diabetes mellitus and who, in turn, have a glycated hemoglobin ≥ 7% (during the last 6 months). * 1b. Patients with a diagnosis of periodontitis (≥ 2 non-adjacent teeth with detectable clinical interproximal attachment loss or, attachment loss ≥ 3mm with depth to probing ≥ 3mm on free faces of ≥ 2 teeth, where the attachment loss was not attributed to non-periodontal causes (Papapanou et al., 2018)). Exclusion Criteria: * 2a. Patients who have received periodontal treatment during the last year. * 2b. Pregnancy/lactation, because they are under treatment under the Explicit Health Guarantee "Oral and Integral Health of Pregnant Women". * 2c. Therapy with antibiotics and/or non-steroidal anti-inflammatory drugs (NSAIDs) in the last 6 months prior to the study.
Where this trial is running
Santiago, Providencia
- Universidad de Chile — Santiago, Providencia, Chile (Recruiting)
Study contacts
- Principal investigator: Melisa Vera, Specialist in periodontics — University of Chile
- Study coordinator: Melisa Vera, Specialist in periodontics
- Email: mvera@odontologia.uchile.cl
- Phone: +56976442451
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.